Literature DB >> 26862046

Serum Vitamin D Levels Not Associated with Atopic Dermatitis Severity.

Renata Robl1, Marjorie Uber1, Kerstin Taniguchi Abagge1, Monica Nunes Lima1, Vânia Oliveira Carvalho1.   

Abstract

BACKGOUND/
OBJECTIVES: The objective of the current study was to determine the relationship between serum vitamin D levels and the severity of atopic dermatitis (AD) in a Brazilian population.
METHODS: This was a cross-sectional study of patients younger than 14 years of age seen from April to November 2013. All patients fulfilled the Hanifin and Rajka Diagnostic Criteria for AD diagnosis. Disease severity was determined using the SCORing Atopic Dermatitis index and classified as mild (<25), moderate (25-50), or severe (>50). Serum vitamin D levels were classified as sufficient (≥30 ng/mL), insufficient (29-21 ng/mL), or deficient (≤20 ng/mL).
RESULTS: A total of 105 patients met the inclusion criteria. Mild AD was diagnosed in 58 (55.2%) children, moderate in 24 (22.8%), and severe in 23 (21.9%). Vitamin D deficiency was observed in 45 individuals (42.9%). Of these, 24 (53.3%) had mild AD, 13 (28.9%) moderate, and 8 (17.7%) severe. Insufficient vitamin D levels were found in 45 (42.9%) individuals; 24 (53.3%) had mild AD, 9 (20.0%) moderate, and 12 (26.7%) severe. Of the 15 individuals (14.2%) with sufficient vitamin D levels, 10 (60.7%) had mild AD, 2 (13.3%) moderate, and 3 (20.0%) severe. The mean vitamin D level was 22.1 ± 7.3 ng/mL in individuals with mild AD, 20.8 ± 6.5 ng/mL in those with moderate AD, and 21.9 ± 9.3 ng/mL in those with severe AD. Variables such as sex, age, skin phototype, season of the year, and bacterial infection were not significantly associated with vitamin D levels.
CONCLUSION: Levels of 25-hydroxyvitamin D were deficient or insufficient in 85% of the children, but serum vitamin D concentrations were not significantly related to AD severity.
© 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26862046     DOI: 10.1111/pde.12795

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  6 in total

1.  The STAT6 inhibitor AS1517499 reduces the risk of asthma in mice with 2,4-dinitrochlorobenzene-induced atopic dermatitis by blocking the STAT6 signaling pathway.

Authors:  Xueying Li; Zhaoqing Han; Feng Wang; Jianou Qiao
Journal:  Allergy Asthma Clin Immunol       Date:  2022-02-17       Impact factor: 3.406

2.  Effect of Vitamin D Serum Levels and Supplementation on Atopic Dermatitis: A Systematic Review and Meta-analysis.

Authors:  Jing Chun Ng; Yik Weng Yew
Journal:  Am J Clin Dermatol       Date:  2022-03-05       Impact factor: 7.403

3.  Oral vitamin D modulates the epidermal expression of the vitamin D receptor and cathelicidin in children with atopic dermatitis.

Authors:  Carolina Cabalín; Guillermo Pérez-Mateluna; Carolina Iturriaga; Carlos A Camargo; Arturo Borzutzky
Journal:  Arch Dermatol Res       Date:  2022-10-22       Impact factor: 3.033

4.  Vitamin D levels and susceptibility to asthma, elevated immunoglobulin E levels, and atopic dermatitis: A Mendelian randomization study.

Authors:  Despoina Manousaki; Lavinia Paternoster; Marie Standl; Miriam F Moffatt; Martin Farrall; Emmanuelle Bouzigon; David P Strachan; Florence Demenais; Mark Lathrop; William O C M Cookson; J Brent Richards
Journal:  PLoS Med       Date:  2017-05-09       Impact factor: 11.069

5.  Serum 25-hydroxyvitamin D levels in patients with skin diseases including psoriasis, infections, and atopic dermatitis.

Authors:  Ulrich Amon; Laura Baier; Raul Yaguboglu; Madeleine Ennis; Michael F Holick; Julian Amon
Journal:  Dermatoendocrinol       Date:  2018-02-22

6.  Vitamin D, cytokine profiles, and disease severity in infants with atopic dermatitis: a single centre, cross-sectional study.

Authors:  Wisnu Barlianto; Desy Wulandari; Tita Luthfia Sari; Vanisia Hayu Firdayanti; Muhammad Irvan Avandi
Journal:  Postepy Dermatol Alergol       Date:  2022-09-01       Impact factor: 1.664

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.